Concert Pharmaceuticals, Inc.

Concert Pharmaceuticals Announces Advancement of Novel Drug Candidates in Kidney Disease and Spasticity

Concert Pharmaceuticals Announces Advancement of Novel Drug Candidates in Kidney Disease and Spasticity

June 20, 2011

LEXINGTON, Mass.--(BUSINESS WIRE)--Concert Pharmaceuticals, Inc. announced today the advancement of two programs from its DCE Platform™ (deuterated chemical entity platform). CTP-499 is progressing into Phase 2 clinical trials for diabetic nephropathy and C-21191 has been selected as a lead candidate for spasticity.

Concert Pharmaceuticals, Inc.

Concert Announces Milestone Achievement in GlaxoSmithKline Collaboration

Concert Announces Milestone Achievement in GlaxoSmithKline Collaboration

June 20, 2011

LEXINGTON, Mass.--(BUSINESS WIRE)--Concert Pharmaceuticals, Inc. today announced that it has achieved a milestone in its strategic alliance with GlaxoSmithKline (GSK) for its HIV protease inhibitor (HIV-PI) development program, resulting in a $4 million milestone payment to Concert. The strategic alliance with GSK was formed in 2009. In the HIV development program a number of deuterium modified-versions of atazanavir were evaluated preclinically, and a subset was selected for further testing in early human clinical studies.

Selecta Biosciences, Inc.

The Juvenile Diabetes Research Foundation and Selecta Biosciences Enter Research Collaboration for Vaccines for Type 1 Diabetes

The Juvenile Diabetes Research Foundation and Selecta Biosciences Enter Research Collaboration for Vaccines for Type 1 Diabetes

June 9, 2011

New York, NY, and Watertown, MA – June 9, 2011 – The Juvenile Diabetes Research Foundation (JDRF) and Selecta Biosciences, Inc. announced today that they have established a research collaboration to support Selecta's development of a vaccine technology, which may subsequently help to better treat and potentially prevent type 1 diabetes.

AVEO Pharmaceuticals, Inc.

AVEO Pharmaceuticals Enters into Worldwide License Agreement with Centocor Ortho Biotech to Develop and Commercialize RON-Targeted Antibodies

AVEO Pharmaceuticals Enters into Worldwide License Agreement with Centocor Ortho Biotech to Develop and Commercialize RON-Targeted Antibodies

May 31, 2011

CAMBRIDGE, Mass., May 31, 2011 (BUSINESS WIRE) -- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced it has entered into an exclusive license agreement with Centocor Ortho Biotech Inc. for the worldwide development and commercialization of AVEO's internally-discovered antibodies targeting the RON (Recepteur d'Origine Nantais) receptor. The RON pathway is believed to be involved in several aspects of cancer development including regulation of tumor growth, survival and metastasis, and bone disruption.

TARIS Biomedical Keeps Delivering Drugs Direct-to-the-Bladder

TARIS Biomedical Keeps Delivering Drugs Direct-to-the-Bladder

May 26, 2011

"...That’s where TARIS Biomedical, launched in 2008, comes in to the picture. It is developing a way to deliver a drug directly into the bladder and keep replenishing its supply so the drug can do its job. In a May 16 interview, CEO Sarma Duddu told me that the key to TARIS’s solution is a device, containing the drug, that goes through the urethra like a string of spaghetti and turns into a small pretzel once it gets to the bladder."

Click Forbes logo to view full story.

BG Medicine, Inc.

BG Medicine Announces Achievement of Two Significant Milestones for AMIPredict™

BG Medicine Announces Achievement of Two Significant Milestones for AMIPredict™

May 11, 2011

WALTHAM, Mass., (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD) announced today that it has successfully completed an important phase in the development of its AMIPredict™ diagnostic product candidate. AMIPredict is being developed to identify patients with a high risk of suffering heart attack or stroke within the next two to four years. The AMIPredict test is an in vitro diagnostic multivariate index assay that simultaneously measures multiple protein biomarkers in blood.

Ze-gen, Inc.

Ze-gen Names Robertson COO and Prendergast CFO

Ze-gen Names Robertson COO and Prendergast CFO

May 16, 2011

Boston, MA— Ze-gen, Inc., a leading developer and integrator of advanced gasification technology to convert waste streams into synthesis gas (syngas), announced today the promotion of David Robertson to Chief Operating Officer and Mark Prendergast to Chief Financial Officer, replacing Neal Isaacson who has served in this role since August 2009.

Seventh Sense Biosystems, Inc.

Seventh Sense Biosystems Secures $4.5M from $10M Series A Offering

Seventh Sense Biosystems Secures $4.5M from $10M Series A Offering

May 11, 2011

Cambridge, Mass., May 11, 2011 - Seventh Sense Biosystems, Inc., a company redefining blood sampling and health diagnostics with its proprietary Touch Activated Phlebotomy™ (TAP) technology platform, announced today that it has secured $4.5 million of a two-tranche $10 million extension of its Series A financing. The funds raised from existing investors, Flagship Ventures, Polaris Venture Partners and Third Rock Ventures, will be used to advance development of the TAP platform, which enables one-step blood collection in a safe, painless and convenient manner.

Scientific founder of AVEO, Dr. DePinho, named President of the MD Anderson Cancer Center

Scientific founder of AVEO, Dr. DePinho, named President of the MD Anderson Cancer Center

May 16, 2011

Flagship congratulates Ron DePinho, Professor of Medicine (Genetics), Harvard Medical School and Director, Belfer Institute for Applied Cancer Science, Dana-Farber Cancer Institute, on his appointment as President of the MD Anderson Cancer Center at the University of Texas.  Dr. DePinho is world renowned for his research into the molecular and biological mechanisms of cancer, aging, and degenerative diseases.

Black Duck Software, Inc.

Black Duck Software Named Winner of the 2011 New England Innovation Awards Program

Black Duck Software Named Winner of the 2011 New England Innovation Awards Program

May 12, 2011

Waltham, MA -- Nine organizations, including profit and nonprofit entities, were honored at the 25th annual SBANE New England Innovation Award (NEIA) festivities last evening at the Westin Hotel here. As further evidence that innovation can thrive in any field of endeavor, the winners represent firms in such diverse fields as regenerative medicine, software development, organic waste treatment, textiles, dry-erase paint technology, youth services, food packaging, plastics industry and science education.